52 results about "Cell mediated immunity" patented technology

The invention belongs to the technical field of biological medicine, and particularly relates to a manganese-doped zeolite imidazole framework and application thereof in tumor radiotherapy. According to the present invention, the new use of the manganese-doped zeolite imidazole framework as the tumor radiosensitizer is found, Mn-ZIF-8 has ray responsiveness, can continuously release Mn < 2 + > ions under X-ray irradiation, and can enhance the activation of a cGAS-STING signal channel so as to promote DCs maturation and antigen presentation, and enhance the T cell mediated immune response, such that the tumor treatment effect is enhanced. Furthermore, the invention provides the Mn-ZIF-8 microneedle, the microneedle has the characteristics of rapid dissolution and controlled release, ensures accurate delivery and continuous action of drugs at tumor sites, reduces systemic toxicity, and can significantly amplify local and systemic immune effects caused by radiotherapy and improve the therapeutic effect when used in combination with an immune checkpoint inhibitor.

The invention discloses a CD40L-IL-2 fusion protein, preparation thereof and application of the CD40L-IL-2 fusion protein in preparation of drugs for treating tumors. The fusion protein comprises a CD40L trimer or a variant thereof, and a cytokine IL-2 or a variant thereof; the CD40L trimer comprises three CD40L monomers which are connected with one another. The fusion protein provided by the invention can synergistically activate APC-dependent antigen presentation and T cell-mediated immune killing to form closed-loop anti-tumor immune response of antigen presentation-immune initiation-effect amplification, and an effective strategy is provided for tumor treatment.

This disclosure provides modified natural killer (NK) cells possessing both NK cell function and dendritic cell function and method of culturing the same. By administration of the modified NK cell, cancer cells in a subject may be effectively inhibited via cell-mediated immunity.

Provided herein are D domain containing polypeptides that specifically bind targets of interest, as are nucleic acids encoding the D domain containing polypeptides, vectors containing the nucleic acids and host cells containing the nucleic acids and vectors. Also provided herein are methods of making and using the D domain containing polypeptides, nucleic acids, vectors and host cells, for example, but not limited to, in diagnostic and therapeutic applications. Also provided herein are multi-functional chimeric antigen receptor (CAR)-based compositions and Adapters and their use in methods of directing immune responses to target cells. In some embodiments, the methods include the use of a CAR expressing cell in combination with an Adapter. The Adapter confers the ability to modulate, alter, and / or direct CAR expressing cell-mediated immune response in vitro and in vivo.

The invention relates to the field of medicine, more specifically to treatment of a condition associated with CD4+ T cell-mediated overactivation of the immune system.

This disclosure relates generally to the field of immunological-based diagnostic assays including an assay to measure cell-mediated immunoresponsiveness. The present disclosure teaches diagnosis of a subject's exposure to an antigen based on cell-mediated immunoresponsiveness with enhanced sensitivity which is achieved by adding a nonreducing sugar during incubation of the sample with the antigen.

Provided herein are immuno-responsive cells expressing a B cell targeting pCAR comprising a 2nd generation chimeric antigen receptor (CAR) and a chimeric co-stimulatory receptor (CCR). Also provided herein are methods of preparing the immuno-responsive cells and methods of directing T cell mediated immune response using the immuno-responsive cells.

The invention relates to bispecific antigen binding proteins (ABP), such as bispecific antibodies, that bind with a first antigen binding site to both leukocyte immunoglobulin-like receptor subfamily B1 (LILRB1) and LILRB2 while not binding to, or binding with significantly less affinity to, leukocyte immunoglobulin-like receptor subfamily A (LILRA). The bispecific ABP of the invention bind with a second antigen binding site to immune checkpoint (molecules) such as PD-1 or PD-L1. The bispecific ABP of the invention can also inhibit the interaction between LILRB1 and / or LILRB2 and a natural ligand of ULRB receptors (e.g. interacting proteins, such as HLA-G) on immune cells and the inhibition of such interaction can reduce immune cell suppression and thereby support anti-infection and anti-tumour immune responses in a subject suffering from such diseases. Bispecific molecules combining LILRB1 / 2 antagonism with inhibition of immune checkpoints, such as the inhibition of the PD-1 / PD-L1 axis, is specifically useful in the treatment of proliferative disorders. Also provided are methods of reducing the immune suppression of cells involved with a cell-mediated immune response, and / or methods for treating infective- and / or proliferative diseases, using an LILRB1 and / or LILRB2 antigen binding protein such as an antibody binding to both LILRB1 and / or LILRB2, as well as certain related aspects including detection, diagnostic and screening methods.

Provided herein are D domain-containing polypeptides that specifically bind to a target of interest, such as nucleic acids encoding the D domain-containing polypeptides, vectors containing the nucleic acids, and host cells containing the nucleic acids and vectors. Also provided herein are methods for producing and using D domain-containing polypeptides, nucleic acids, vectors, and host cells, for example, but not limited to, in diagnostic and therapeutic applications. Also provided herein are multifunctional chimeric antigen receptor (CAR)-based compositions and adapters, and their use in methods for directing an immune response against target cells. In some embodiments, the method includes the use of CAR-expressing cells in combination with an adapter. The adapter confers the ability to modulate, alter, and / or direct the cell-mediated immune response of the CAR-expressing cells in vitro and in vivo.

The present disclosure relates to a method for increasing cell-mediated immunity against Varicella-Zoster Virus (VZV) in a human subject in need thereof by administration of an immunogenic composition comprising an effective amount of a VZV glycoprotein E antigen and an oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif. The immunogenic composition is suitable for the prevention of varicella zoster and / or post-herpetic neuralgia.

The application discloses a CD40L-IL-2 fusion protein and a preparation method and application thereof in preparing a tumor treatment drug. The fusion protein comprises a CD40L trimer or a variant thereof and a cytokine IL-2 or a variant thereof; the CD40L trimer comprises three CD40L monomers connected. The fusion protein provided by the application can synergistically activate APC-dependent antigen presentation and T cell-mediated immune killing, forms a closed-loop anti-tumor immune response of 'antigen presentation-immune initiation-effect amplification', and provides an effective strategy for treating tumors.

The invention discloses a fusion protein containing CD40L and IL7 and application of the fusion protein in preparation of a medicine for treating tumors. The fusion protein comprises a trimer containing CD40L or a variant thereof, and a cytokine IL-7 or a variant thereof; the CD40L trimer comprises three CD40L monomers which are connected with one another. The fusion protein provided by the invention can synergistically activate APC-dependent antigen presentation and T cell-mediated immune killing to form closed-loop anti-tumor immune response of antigen presentation-immune initiation-effect amplification, and an effective strategy is provided for tumor treatment.

Mammals rely on adaptive immunity to protect against infections and tumors, with the thymus playing a crucial role by producing T cells that target infected or cancerous cells. The thymus, however, undergoes functional decline with age, significantly impairing the immune system in the elderly. To investigate reversing this decline, compositions and methods for activation and differentiation of T cell progenitors in extrathymic tissues are disclosed that stimulate production of differentiated T cells. For example, LNP-mediated delivery of mRNAs encoding DLL-1, IL-7, and FLT3L to the liver is shown to create a temporary site for T cell maturation that enhances T cell-mediated immunity in aged mice without causing autoimmunity. This approach facilitates ectopic T cell development from hematopoietic precursors and activates dendritic cells, providing evidence that engineering adaptive immunity in vivo can effectively mitigate immune aging.

The invention discloses a combined application of a PARP7 inhibitor or a pharmaceutically acceptable salt thereof and temozolomide, which is characterized in that the PARP7 inhibitor is used for recovering an I-type interferon signal channel and promoting T cell-mediated immune response and polarization of TAMs to M1 type, so that the side effect of temozolomide is reduced, the sensitivity of temozolomide is enhanced, and an excellent synergistic anti-tumor effect is achieved; the traditional Chinese medicine composition especially has a remarkable curative effect on brain glioma with high malignant degree, and is safe and effective.

This invention relates to the field of pharmaceutical technology, specifically proposing the application of ligustilide in the preparation of drugs for inhibiting and / or preventing and / or alleviating and / or treating lung tumors to address the current lack of natural drugs for lung cancer prevention. Lung tumors are nitrosamine-induced carcinogenesis of lung tissue. The invention relates to a pharmaceutical preparation for inhibiting and / or preventing and / or alleviating and / or treating lung tumors, comprising an active ingredient and pharmaceutically acceptable excipients; wherein the active ingredient is ligustilide. Ligustilide directly targets the STING protein, activates the cGAS-STING pathway, promotes STING phosphorylation and cell-mediated immune surveillance, while simultaneously regulating ROS homeostasis and the inflammatory microenvironment, reducing nitrosamine damage to lung epithelial cells, and preventing nitrosamine-induced lung carcinogenesis.

This invention provides transformed cells for the production of transformed replica pigs for xenotransplantation. [Solution] This invention relates to a transformed replica pig from which the heterologous antigens GGTA1, CMAH, iGb3s, β4GalNT2, and β2M genes have been removed from a PERV Envelope C-negative base, and a method for producing the same. The transformed replica pig according to the present invention can overcome hyperacute and antigen-antibody-mediated immune rejection reactions and T-cell-mediated immune rejection reactions without causing the transfer of porcine endogenous retroviruses that occur in xenologous organ transplantation, and can be usefully utilized as a donor animal for interspecies organ and cell transplantation.

Provided herein are D domain containing polypeptides that specifically bind targets of interest, as are nucleic acids encoding the D domain containing polypeptides, vectors containing the nucleic acids and host cells containing the nucleic acids and vectors. Also provided herein are methods of making and using the D domain containing polypeptides, nucleic acids, vectors and host cells, for example, but not limited to, in diagnostic and therapeutic applications. Also provided herein are multi-functional chimeric antigen receptor (CAR)-based compositions and Adapters and their use in methods of directing immune responses to target cells. In some embodiments, the methods include the use of a CAR expressing cell in combination with an Adapter. The Adapter confers the ability to modulate, alter, and / or direct CAR expressing cell-mediated immune response in vitro and in vivo.

The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and / or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.

The invention discloses a nano immunotherapeutic agent and a preparation method and application thereof, and the nano immunotherapeutic agent is based on mesoporous polydopamine (MPDA) nanoparticles, His tag loaded IL-2 and syloserpine (Syr), and can enhance T cell mediated immune response through mild photothermal therapy and lactic acid regulation. Syr is used as a monocarboxylic acid transporter inhibitor and can effectively reduce the lactic acid level in a tumor microenvironment, so that the function of IL-2 is recovered; meanwhile, the mPTT initiated by the MPDA nanoparticles can convert a cold tumor into a hot tumor, so that the sensitivity of an immune checkpoint inhibition therapy is improved. The Syr / IL-2 (at) MPDA significantly improves the anti-tumor immune response by cooperating with T cell activation, lactic acid regulation and mPTT. The invention provides an immunotherapy strategy for enhancing T cell mediation through mPTT and lactic acid regulation based on the nano immunotherapy agent.

The present disclosure relates to isolated monoclonal antibodies or antigen-binding fragments thereof that specifically bind to PD-1 and block the interaction between PD-1 and PD-L1 / PD-L2. The present disclosure also relates to antibodies that are chimeric antibodies, humanized antibodies, bispecific antibodies, derivatized antibodies, single-chain antibodies, portions of fusion proteins, or bispecific antibodies. Nucleic acid molecules encoding the antibodies, hybridomas, and methods for expressing the antibodies are also provided. Pharmaceutical compositions comprising the antibodies are also provided. The present disclosure also provides uses of these antibodies for enhancing T cell function and upregulating cell-mediated immune responses for the treatment and prevention of various diseases.

The invention discloses a bacterial outer membrane vesicle. The bacterial outer membrane vesicle is obtained through induced expression and purification of a pseudomonas aeruginosa recombinant expression vector. The pseudomonas aeruginosa recombinant expression vector is obtained by knocking out an htrB1 gene on a wild type pseudomonas aeruginosa PAO1 strain; or the pseudomonas aeruginosa recombinant expression vector is obtained by knocking out the htrB1 gene and the tolB gene on the wild type pseudomonas aeruginosa PAO1 strain. The invention also discloses an application of the bacterial outer membrane vesicle in preparation of a pseudomonas aeruginosa vaccine. The pseudomonas aeruginosa vaccine can cause humoral immune response and cell-mediated immune response. According to the invention, a genome of pseudomonas aeruginosa is edited by utilizing a CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats-associated 9) technology, and an OMV attenuated pseudomonas aeruginosa strain and an OMV attenuated and productive pseudomonas aeruginosa strain are constructed. The OMV of the constructed strain is taken as an antigen, and broad-spectrum protective pseudomonas aeruginosa vaccines aiming at different serotypes can be developed.

The present application relates to a kind of anti-PD-L1 and HHLA2 bispecific antibody and its preparation method and application.The bispecific antibody includes PD-L1 binding domain and HHLA2 binding domain, the PD-L1 binding domain includes anti-PD-L1 monoclonal antibody, the HHLA2 binding domain includes the variable region of anti-HHLA2 nanobody;The variable region of anti-HHLA2 nanobody is connected with the N terminal or C terminal of the light chain or heavy chain of anti-PD-L1 monoclonal antibody by flexible linker.The present application constructs specific structure anti-HHLA2 and PD-L1 bispecific antibody, with high specificity and affinity, can up-regulate cell-mediated immune response, and enhance the function of T cell and NK cell in tumor microenvironment.In addition, bispecific antibody drug conjugate can be further developed, with higher efficient tumor cell specific killing ability, provide new method, new idea for treating tumor and infectious disease.

A composition that modulates cellular immunity in animals includes an ingredient derived from a plant. Such an ingredient may be referred to as “plant-derived” or “plant-based.” The plant-derived ingredient modulates cellular immunity in animals. Such a plant-derived ingredient may include an extract, fraction, or isolate from a seed of a plant, such as a seed of a plant from the family Brassicaceae. A method for modulating cellular immunity in an animal includes administering a plant-derived composition to the animal in amount that will cause the animal to elicit a cell-mediated immune response.

The present invention provides bispecific binding proteins binding MUC-1 and CD40 and pharmaceutical compositions, and their use to upregulate cell-mediated immune responses and for the treatment of cancer.

The present disclosure provides antibodies or antigen-binding fragments thereof that bind to human CD137, nucleic acids encoding the antibodies or antigen-binding fragments thereof, therapeutic compositions of the antibodies or antigen-binding fragments thereof, and their uses for enhancing T cell function to upregulate cell-mediated immune response and for treating T cell dysfunction disorders, such as tumor immunity, and for treating cancer.

The present application provides anti-ROR1 monoclonal antibodies, antigen-binding portions thereof, therapeutic compositions thereof, and / or nucleic acids encoding the same, and their use in upregulating T cell function to enhance cell-mediated immune responses in the treatment of cancer and other T cell dysfunction.

Provided herein are compositions and methods for inducing an immune response using small circular ribonucleic acid (circRNA) molecules. In particular, the compositions comprise a small circRNA encoding at least one antigen or immunogenic peptide fragment, wherein the composition is self-adjuvanted and configured to elicit a T-cell–mediated immune response.

The present application provides anti-4-1BB monoclonal antibodies, antigen-binding portions thereof, therapeutic compositions thereof, and / or nucleic acids encoding the same, and their use in upregulating T cell function to enhance cell-mediated immune responses in the treatment of cancer and other T cell dysfunction.

Provided herein are D domain containing polypeptides that specifically bind targets of interest, as are nucleic acids encoding the D domain containing polypeptides, vectors containing the nucleic acids and host cells containing the nucleic acids and vectors. Also provided herein are methods of making and using the D domain containing polypeptides, nucleic acids, vectors and host cells, for example, but not limited to, in diagnostic and therapeutic applications. Also provided herein are multi-functional chimeric antigen receptor (CAR)-based compositions and Adapters and their use in methods of directing immune responses to target cells. In some embodiments, the methods include the use of a CAR expressing cell in combination with an Adapter. The Adapter confers the ability to modulate, alter, and / or direct CAR expressing cell-mediated immune response in vitro and in vivo.

The present invention relates to a composition for inducing a T cell mediated immune response for use in the treatment or prevention of prostate cancer, the composition comprising a modified vaccinia virus Ankara (MVA) vector that expresses a 5T4 antigen polypeptide under the control of a poxvirus F11 promoter. Suitably, the poxvirus F11 promoter is an endogenous MVA F11 promoter. More suitably, the vector expresses a polypeptide having the amino acid sequence represented by SEQ ID NO: 1 or the vector expresses a polypeptide encoded by a polynucleotide having the nucleic acid sequence represented by SEQ ID NO: 2. The invention also relates to uses and methods.